secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2022-02-10T23:59:59+00:00
Accession:  0001437749-22-003026
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma (INBP) Q1 net income $1.0M vs $1.2M; revenue up 2.1%
-------------------------------------------------------------------------

- Revenue for quarter ended Dec 31, 2021: $14.6M, up 2.1% YoY from $14.3M.
- Operating income fell to $0.7M from $1.2M; net income $1.0M vs $1.2M.
- EPS basic unchanged at $0.04; diluted $0.03 vs $0.04.
- Six-month revenue down 7.1% to $27.3M; net income $1.5M vs $2.3M.
- Co-CEOs attribute 6-month decline to prior year's COVID-related safety stock and demand.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922003026/0001437749-22-003026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774922003026/inbp20220209_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-003026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer